Walleye Capital LLC Crispr Therapeutics Ag Put Options Transaction History

Walleye Capital LLC

10 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 14, 2024	SELL	$51.17 - $68.18 $394,009 - $524,986	-7,700 Reduced 53.47%	6,700 $361,000
Q1 2024 May 15, 2024	SELL	$60.67 - $89.12 $1.01 Million - $1.48 Million	-16,600 Reduced 53.55%	14,400 $981,000
Q4 2023 Feb 14, 2024	BUY	$38.62 - $72.18 $370,752 - $692,928	9,600 Added 44.86%	31,000 $1.94 Million
Q2 2023 Aug 14, 2023	BUY	$43.47 - $67.77 $291,249 - $454,059	6,700 Added 45.58%	21,400 $1.2 Million
Q1 2023 May 15, 2023	BUY	$41.0 - $56.12 $118,900 - $162,748	2,900 Added 24.58%	14,700 $664,000
Q4 2022 Feb 14, 2023	BUY	$39.19 - $65.67 $27,433 - $45,969	700 Added 6.31%	11,800 $479,000
Q3 2022 Nov 14, 2022	BUY	$61.1 - $83.78 $678,210 - $929,958	11,100 New	11,100 $725,000
Q4 2019 Feb 14, 2020	SELL	$36.68 - $73.13 $319,116 - $636,231	-8,700 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$40.99 - $52.56 $299,227 - $383,688	7,300 Added 521.43%	8,700 $357,000
Q1 2019 May 15, 2019	BUY	$28.02 - $40.87 $39,228 - $57,218	1,400 New	1,400 $50,000

523

58M

1.73M

1.84M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.87B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.